LT3570882T - Nauja stabili kompozicija, skirta antikūnams fxia - Google Patents

Nauja stabili kompozicija, skirta antikūnams fxia

Info

Publication number
LT3570882T
LT3570882T LTEPPCT/EP2018/050951T LT18050951T LT3570882T LT 3570882 T LT3570882 T LT 3570882T LT 18050951 T LT18050951 T LT 18050951T LT 3570882 T LT3570882 T LT 3570882T
Authority
LT
Lithuania
Prior art keywords
stable formulation
novel stable
fxia antibodies
fxia
antibodies
Prior art date
Application number
LTEPPCT/EP2018/050951T
Other languages
English (en)
Inventor
Carsten Olbrich
Thomas Trill
Marieke Veurink
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of LT3570882T publication Critical patent/LT3570882T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
LTEPPCT/EP2018/050951T 2017-01-19 2018-01-16 Nauja stabili kompozicija, skirta antikūnams fxia LT3570882T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17152108 2017-01-19
PCT/EP2018/050951 WO2018134184A1 (en) 2017-01-19 2018-01-16 Novel stable formulation for fxia antibodies

Publications (1)

Publication Number Publication Date
LT3570882T true LT3570882T (lt) 2021-12-10

Family

ID=57914707

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2018/050951T LT3570882T (lt) 2017-01-19 2018-01-16 Nauja stabili kompozicija, skirta antikūnams fxia

Country Status (25)

Country Link
US (1) US20190367636A1 (lt)
EP (1) EP3570882B1 (lt)
JP (1) JP7072577B2 (lt)
KR (1) KR20190105588A (lt)
CN (1) CN110234353B (lt)
AR (1) AR110762A1 (lt)
AU (1) AU2018209118A1 (lt)
BR (1) BR112019014785A2 (lt)
CA (1) CA3050172A1 (lt)
CY (1) CY1124922T1 (lt)
DK (1) DK3570882T3 (lt)
ES (1) ES2904474T3 (lt)
HR (1) HRP20220011T1 (lt)
HU (1) HUE056858T2 (lt)
IL (1) IL267917B2 (lt)
LT (1) LT3570882T (lt)
MX (1) MX2019008544A (lt)
PE (1) PE20191476A1 (lt)
PL (1) PL3570882T3 (lt)
PT (1) PT3570882T (lt)
RS (1) RS62780B1 (lt)
SG (1) SG11201906557UA (lt)
SI (1) SI3570882T1 (lt)
TW (1) TWI753087B (lt)
WO (1) WO2018134184A1 (lt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36751A (es) 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
IL267538B2 (en) 2016-12-23 2024-05-01 Novartis Ag Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
BR112022012064A2 (pt) * 2019-12-20 2022-08-30 Anthos Therapeutics Inc Formulação de distribuição de fármaco intravenosa, frasco compreendendo a mesma e método de tratamento de um sujeito acometido por ou em risco de desenvolver um distúrbio tromboembólico
CR20220500A (es) * 2020-04-03 2022-11-18 Bayer Ag Formulaciones farmacéuticas de profármacos de adrenomedulina a base de polietilenglicol y uso
CA3188566A1 (en) 2020-07-03 2022-01-06 Suzhou Alphamab Co., Ltd. Coagulation factor xi (fxi) binding protein
EP4259200A1 (en) * 2020-12-11 2023-10-18 Boehringer Ingelheim International GmbH Formulation for multi-purpose application
CN118382643A (zh) * 2022-01-05 2024-07-23 上海迈晋生物医药科技有限公司 一种包含抗FXI/FXIa抗体的药物组合物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8632778B2 (en) * 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
AU2003293543A1 (en) * 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
CN102159204B (zh) * 2008-09-19 2015-04-01 辉瑞公司 稳定的液体抗体制剂
JP5933975B2 (ja) * 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
EP2847228B1 (en) 2012-05-10 2018-07-25 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
RS58856B1 (sr) * 2013-10-25 2019-07-31 Bayer Pharma AG Nova stabilna formulacija

Also Published As

Publication number Publication date
TW201831170A (zh) 2018-09-01
CA3050172A1 (en) 2018-07-26
KR20190105588A (ko) 2019-09-17
SG11201906557UA (en) 2019-08-27
US20190367636A1 (en) 2019-12-05
ES2904474T3 (es) 2022-04-05
HUE056858T2 (hu) 2022-03-28
JP7072577B2 (ja) 2022-05-20
IL267917B1 (en) 2023-06-01
CN110234353A (zh) 2019-09-13
RS62780B1 (sr) 2022-01-31
HRP20220011T1 (hr) 2022-04-01
TWI753087B (zh) 2022-01-21
WO2018134184A1 (en) 2018-07-26
PL3570882T3 (pl) 2022-02-07
EP3570882B1 (en) 2021-11-17
SI3570882T1 (sl) 2022-01-31
RU2019125947A3 (lt) 2021-05-25
BR112019014785A2 (pt) 2020-05-12
AU2018209118A1 (en) 2019-07-11
EP3570882A1 (en) 2019-11-27
MX2019008544A (es) 2019-10-07
CY1124922T1 (el) 2023-01-05
AR110762A1 (es) 2019-05-02
CN110234353B (zh) 2023-07-04
DK3570882T3 (da) 2022-01-10
IL267917B2 (en) 2023-10-01
RU2019125947A (ru) 2021-02-19
IL267917A (en) 2019-09-26
PT3570882T (pt) 2022-01-11
JP2020506175A (ja) 2020-02-27
PE20191476A1 (es) 2019-10-16

Similar Documents

Publication Publication Date Title
IL269499A (en) Stable antibody formulation
IL268517A (en) Anti-tigit antibodies
IL325604A (en) New anti-CD3 epsilon antibodies
IL273576A (en) Antibody for multiple individuals
SG11202000660QA (en) Anti-tigit antibodies
PL3625259T3 (pl) Przeciwciała anty-sirpalfa
LT3606954T (lt) Anti-lag3 antikūnai
GB201709808D0 (en) Antibodies
IL267917A (en) A new stable formulation for fxia antibodies
SG11202002489YA (en) Anti-transthyretin antibodies
SG10201914130VA (en) GARP-TGF-β ANTIBODIES
ZA201906981B (en) Stable multispecific antibodies
IL275187A (en) Anti-alpha-synuclein antibodies
GB201720970D0 (en) Antibodies
IL271067A (en) Anti-trkb antibodies
GB201711785D0 (en) Antibodies
HK40033943A (en) Novel anti-cd3epsilon antibodies
GB201717006D0 (en) Anti-OPG antibodies
GB201709818D0 (en) Antibodies
GB201703071D0 (en) Antibodies
GB201701416D0 (en) Anti-OPG antibodies